Reading GNPX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GNPX free→Reading GNPX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GNPX free→QuarterlyIQ Insights · GNPX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. Risk Factors The Company is including the below update to its risk factors, for the purpose of supplementing and updating the disclosure contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026, and its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, filed with the Securities and Exchange Commission on May 13, 2026. Our common stock is currently listed o…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 10, 2026, Genprex, Inc. (“Genprex” or the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the Company’s common stock closed at less than $1.00 per share over the previous 30 consecutive business days and as a result is not in compliance with the $1.00 minimum bid price req…
Other Events. On May 26, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing that its research collaborators’ abstract was recently published at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting. The abstract details positive clinical data from studies of predictive biomarkers in patients receiving its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of lung cancer. The press release noted that this cl…
Other Events. On May 14, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing that its research collaborators presented positive preclinical data on the Company’s diabetes gene therapy drug candidate at the 2026 American Society of Gene and Cell Therapy (“ASGCT”) Annual Meeting on May 13, 2026 in Boston, Massachusetts. The collaborators presented preclinical data demonstrating that the diabetes gene therapy (Pdx1/MafA gene therapy, “PM” or “GPX-002”) can reverse…
Other Events. On April 30, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release in which it announced that the Israel Patent Office (“ILPO”) has granted Genprex a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer. The press release noted that this strategic expansion builds upon the Company’s existing intellectual property in numerous major markets worldwide and underscores the scienti…
Other Events. On April 28, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing that its research collaborators will present positive preclinical data on the Company’s diabetes gene therapy drug candidate at the upcoming 2026 American Society of Gene and Cell Therapy (“ASGCT”) Annual Meeting, taking place May 11-15, 2026 in Boston, Massachusetts. The collaborators will present preclinical data demonstrating that the diabetes gene therapy (Pdx1/MafA gene therapy,…
Other Events. On April 21, 2026, Genprex issued a press release announcing it has entered into a new Sponsored Research Agreement (“SRA”) with The University of Texas MD Anderson Cancer Center (“UT MD Anderson”) to study biomarkers that may predict patient response to Reqorsa® Gene Therapy (quaratusugene ozeplasmid), the Company’s lead drug candidate that is in development for the treatment of non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Shortly after it was found…
Other Events. On March 18, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing that its research collaborators will present at the upcoming 2026 American Association for Cancer Research (“AACR”) Annual Meeting being held April 17-22, 2026 in San Diego, California. The collaborators will present positive preclinical data from studies of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid, also referred to as “Quar Oze”), for the treatment of…
Other Events. On February 23, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release in which it announced that the Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies to treat cancer. Also, the European Patent Office has issued a Decision to Grant relating to a patent for the combination of REQORSA and PD-1 antibodies to treat cancer. Genprex maintains an exclusive lice…
Other Events. On February 10, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release in which it announced that IP Australia, the Australian government agency responsible for administering Australia’s intellectual property rights system, has issued a Notice of Acceptance, on February 5, 2026, of the Genprex patent application claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies for the treatment of cancers. The subject claims have been successfully g…
Other Events. On January 7, 2026, Genprex issued a press release announcing clinical program updates on its diabetes gene therapy program for GPX-002, the Company’s diabetes gene therapy drug candidate, detailing recent achievements and future advancements, including the initiation of the Company’s preclinical research in Type 2 diabetic (“T2D”) animal models, the execution of the Company’s strategic plan to transfer production of GPX-002 to an experienced contract development and manufacturi…
Other Events. On January 6, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing positive preliminary preclinical data from the study of GPX-002 in Type 2 diabetic (“T2D”) animal studies, which demonstrates in vivo proof-of-concept for novel diabetes gene therapy in T2D non-human primates (“NHP”) and rejuvenated exhausted beta cells and normalized glucose levels in T2D mice. GPX-002 is the Company’s diabetes gene therapy drug candidate which based on the prelimin…
Other Items . As previously disclosed, on August 19, 2025, Genprex, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for the continued listing of the Company’s common stock (the “Common Stock”) on the Nasdaq Capital Market, under Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). Also as previousl…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard ; Transfer of Listing . As previously disclosed, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market, LLC (“Nasdaq”) had previously notified the Company on October 13, 2025 that the Panel had granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) and the minimum sto…
Other Events. On November 21, 2025, Genprex, Inc. (the “Company”) filed a prospectus supplement dated November 21, 2025 (the “Prospectus Supplement”) with the Securities and Exchange Commission for the offer and sale of additional shares of its common stock, par value $0.001 per share having an aggregate offering price of up to $75,000,000 (the “Shares”), pursuant to that certain At the Market Offering Agreement, dated December 13, 2023, by and between the Company and H.C. Wainwright & Co., L…
Other Events. On November 19, 2025, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing that the Company has added Gabrail Cancer Center in Canton, Ohio, as a new clinical trial site for the Acclaim-1 and Acclaim-3 clinical trials studying its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in lung cancer. In addition, the Company expects to add and open additional clinical trial sites for its Acclaim clinical trials over the coming months in an…
Other Events. On November 18, 2025, Genprex, Inc. (“Genprex” or the “Company”) issued a press release in which it announced that the United States Patent and Trademark Office has granted Genprex a patent that covers the use of the Company’s lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in combination with PD-L1 antibodies, such as Tecentriq®, through 2037. The press release noted that in the Acclaim-3 clinical trial, the Company is combining REQORSA with Tecentriq, a…
Other Events. On November 4, 2025, Genprex, Inc. (“Genprex” or the “Company”) issued a press release in which it announced that the European Patent Office has communicated its intent to grant Genprex a patent for the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer. The press release also noted that this patent, if granted, will expand on the previously granted patents for REQORSA in combination with PD-1 antibodies, which…
Entry into a Material Definitive Agreement. The Offering On October 28, 2025, Genprex, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors named therein (the “Purchasers”) pursuant to which the Company agreed to sell, in a registered direct offering (the “Registered Direct Offering”) priced at the market under Nasdaq rules, an aggregate of 377,780 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common…
Unregistered Sales of Equity Securities. The information set forth in
Other Events. On October 28, 2025, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing that its research collaborators presented positive preclinical data at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics which took place October 22-26, 2025 at the Hynes Convention Center in Boston. The collaborators presented positive preclinical data from a study of Genprex’s lead drug candidate, Reqorsa® Gene Therapy (quaratusugene oze…
Entry into a Material Definitive Agreement. The Offering On October 23, 2025, Genprex, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors named therein (the “Purchasers”) pursuant to which the Company agreed to sell, in a registered direct offering (the “Registered Direct Offering”) priced at the market under Nasdaq rules, an aggregate of 243,622 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common…
Unregistered Sales of Equity Securities. The information set forth in
Other Events. On October 23, 2025, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing that its research collaborators will present positive preclinical data at the upcoming 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 at the Hynes Convention Center in Boston. The collaborators will present positive preclinical data from a study of Genprex’s lead drug candidate, Reqorsa® Gene Therapy (quarat…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard ; Transfer of Listing. On October 13, 2025, the Nasdaq Hearings Panel (the “Panel”) notified Genprex, Inc. (the “Company” or “Genprex”) that it has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) and the minimum stockholders’ equity requirement for continued listing on the…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.